Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25
billion of senior notes, consisting of $750 million aggregate principal
amount of 3.000% senior notes due 2027 and $500 million aggregate
principal amount of 3.950% senior notes due 2047, in an underwritten
public offering.
Zoetis intends to use the net proceeds to repay, prior to maturity, the
principal (including a make-whole amount) of its 1.875% senior notes due
2018 in the aggregate principal amount of $750 million; and for general
corporate purposes. The offering is expected to close on September 12,
2017, subject to customary closing conditions.
Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan
Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and
MUFG Securities Americas Inc. are acting as joint book-running managers
of the underwriters. The final prospectus supplement and accompanying
prospectus, when available, may be accessed through the SEC’s website at www.sec.gov.
Alternatively, the issuer, the underwriters or any dealer participating
in the offering will arrange to send you the prospectus and prospectus
supplement if you request it by calling Barclays at 1-888-603-5847, BofA
Merrill Lynch at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P.
Morgan at 212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration statement that
has become effective under the Securities Act of 1933, as amended. These
securities are only offered by means of the prospectus supplement and
prospectus relating to the offering. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any offer or sale of these securities in any state or
other jurisdiction, where the offer, solicitation or sale of these
securities would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its
customers and their businesses. Building on more than 60 years of
experience in animal health, Zoetis discovers, develops, manufactures
and markets veterinary vaccines and medicines, complemented by
diagnostic products, genetic tests, biodevices and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
more than 100 countries.
DISCLOSURE NOTICES
Forward-Looking Statements
: This
press release contains forward-looking statements, which reflect the
current views of Zoetis with respect to business plans or prospects,
future operating or financial performance, future guidance, future
operating models, expectations regarding products, future use of cash
and dividend payments, tax rate and tax regimes, changes in the tax
regimes and laws in other jurisdictions, and other future events. These
statements are not guarantees of future performance or actions.
Forward-looking statements are subject to risks and uncertainties. If
one or more of these risks or uncertainties materialize, or if
management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as of
the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in the prospectus supplement and accompanying prospectus under the
caption “Risk Factors” and in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2016, including in the sections thereof
captioned “Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form
10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at
www.sec.gov
,
Zoetis’ website, or on request from Zoetis.
Zoetis Inc.
Media:
Bill Price, 1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investors:
Steve Frank, 1-973-822-7141 (o)
steve.frank@zoetis.com